聯亞藥30噴到215~但明天應該會GG (第2頁)

聯亞疫苗主持人打了莫德納原因曝光 sorry

https://ctee.com.tw/livenews/ch/chinatimes/20210628002369-260405

怎麼不是打高端...

查了聯亞只是代工

https://vaxxinity.com/
Vaxxinity Signs Purchase Order with the Government of Paraguay for 1 Million Doses of Vaxxinity’s UB-612 COVID-19 Vaccine
June 21, 2021
Upon TFDA issuance of an EUA in Taiwan, an EUA will be issued in Paraguay and Vaxxinity will deliver 1MM doses of its COVID-19 vaccine to Paraguay
Paraguay suffers one of the worst COVID-19 outbreaks per capita in the world, with more than 400,000 total cases and 11,000 deaths within the population of 7 million
Vaxxinity’s commitment to Paraguay demonstrates one of its core missions to democratize health worldwide, focusing on countries with the greatest need
The Vaxxinity UB-612 vaccine is the first Multitope protein/synthetic peptide vaccine to fight the SARS-CoV-2 virus. The UB-612 vaccine elicits broad humoral or cellular immune responses against several viral proteins to protect against COVID-19.

DALLAS (June 21, 2021) – Vaxxinity, a U.S. company, pioneering the development of a new class of immunotherapeutic vaccines, in close collaboration with UBI-Asia, has announced a purchase order for its COVID-19 vaccine, UB-612, with the Government of Paraguay, contingent upon issuance of an Emergency Use Authorization (EUA) by the Taiwanese Food and Drug Administration (TFDA), which will trigger an EUA in Paraguay. The order was signed on June 16 in Asunción, by Dr. Julio Borba, Paraguay Minister of Health and Social Welfare, and Jon Harrison, Vaxxinity Chief Strategy Officer. Ambassador José Han, Taiwan’s Ambassador to Paraguay, was also present (pictured).

The UB-612 vaccine is expected to be delivered later this summer, pending issuance of an EUA by the TFDA and subsequent registration by Paraguay’s National Health Surveillance Authority (DINAVISA). As the Ministry of Health and Social Welfare noted the leadership shown on June 16 by the Government of Paraguay guarantees that Paraguay will be one of the first countries in the world to receive UB-612 once it is issued an EUA.

“Vaxxinity’s foundation is a commitment to democratizing healthcare worldwide.” said Lou Reese, co-founder and executive chairman of Vaxxinity. “Whether by cost, geography, healthcare infrastructure, discrimination, isolation, exclusion, economic or social status or legacy experience, vaccines to fight the global COVID-19 pandemic have not been distributed equitably to date. Vaxxinity has prioritized its focus on UB-612, while continuing development of the other vaccines in its pipeline, in order to rapidly develop, manufacture, and distribute vaccines to help combat the global COVID-19 pandemic in countries most in need.”

Vaxxinity, in close collaboration with its partner, UBI-Asia, is completing a large Phase 2 clinical trial of UB-612 in Taiwan, with support from Taiwan’s Ministry of Health and Welfare, and will soon begin its Phase 2/3 efficacy trial in India in partnership with Aurobindo. Vaxxinity has also announced a global logistics partnership with Maersk, the world’s largest shipping and integrated logistics provider, that creates a framework for all transportation and supply chain services that will be needed to deliver UB-612 around the world.

The Vaxxinity UB-612 vaccine is the first Multitope protein/synthetic peptide vaccine to fight the SARS-CoV-2 virus. The UB-612 vaccine elicits broad humoral or cellular immune responses against several viral proteins to protect against COVID-19.

“Our vaccine is designed to stimulate broadly protective immunity protecting the body from future SARS-Cov-2 exposure,” says Mei Mei Hu, co-founder and CEO of Vaxxinity. “In addition, our UB-612 vaccine can be stored at the standard refrigeration range, enabling its distribution using cold-chain solutions readily available in the countries impacted by the COVID-19 pandemic the most. This supports our mission to spearhead the democratization of global healthcare, which will lead to healthier, sustainable and more productive communities across the world.”

About Vaxxinity, Inc.

Vaxxinity, Inc. is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with partners in the United States, Latin America, Europe and Asia, the company’s proprietary Multitope technology platform has enabled the innovation of synthetic peptide vaccines designed to treat and prevent infectious diseases, including COVID-19, and chronic diseases, such as Alzheimer’s, Parkinson’s, migraine, and hypercholesterolemia. Unlike vaccines designed to prevent exogenous diseases, Vaxxinity’s chronic disease pipeline is designed to train the body to produce its own antibodies against internal targets of disease. This comes with practical administrative and cost advantages versus monoclonal antibodies, meaning that Vaxxinity may if approved offer infrequent IM injection versus frequent IV infusion, and lower costs.

新聞稿
https://www.businesswire.com/news/home/20210621005250/en/Vaxxinity-Signs-Purchase-Order-with-the-Government-of-Paraguay-for-1-Million-Doses-of-Vaxxinity%E2%80%99s-UB-612-COVID-19-Vaccine

Vaxxinity 與巴拉圭政府簽署採購訂單，購買 100 萬劑 Vaxxinity 的 UB-612 COVID-19 疫苗

聯繫人
Diane Murphy, Vaxxinity, Inc.
+1.310.658.8756
[email protected]

聯亞主持人打莫德納這裡就是貓膩了

前線應該都打AZ。因為莫德納5月份才來台灣的阿。台灣最早進來的國外疫苗是AZ

這種說法.....中國附醫副院長黃高彬表示聯亞的疫苗不管對英國Alpha還是印度Delta變種病毒株保護力可達90％以上，他也坦言自己原本想打聯亞疫苗，但因為身兼疾管署中區疫情指揮官必須經常深入虎穴，因而接種莫德納疫苗。

那撐到莫德納來台灣之前。都不危險。挖鼻孔

https://www.ndtv.com/india-news/covovax-vaccine-nod-likely-by-september-need-more-data-for-covid-19-delta-variant-novavax-ceo-stanley-erck-2476202

跟聯亞一樣的蛋白技術。Novavax 三期都做了。不保證 Delta 變體的有效性數據。

所以超英國趕過美國。已經在發生中。

大家要支持國產疫苗二期就能這麼厲害。彎道甩尾超車，Novavax....

打兩劑就無敵了。你們這些刁民。看吧
https://udn.com/news/story/122190/5565259

聯亞藥30噴到215~但明天應該會GG

小惡魔新聞台

今日熱門文章 網友點擊推薦！

今日熱門文章　網友點擊推薦！